Group 1 - Longhang Asset recently conducted research on Yifang Bio, highlighting the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - The drug Gesorex (brand name Anfangning) received approval from the National Medical Products Administration for the treatment of advanced non-small cell lung cancer (NSCLC) in adults with KRS G12C mutations, with multiple clinical studies ongoing [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1] Group 2 - Longhang Asset Management Company is a professional asset management firm based in Shanghai, with a core team possessing 18 years of industry investment experience [2] - The company adheres to a value investment philosophy, utilizing various financial tools to manage client assets for sustainable growth [2] - Longhang Asset emphasizes research-driven investment and the importance of a rigorous scientific investment process [2]

调研纪要：益方生物介绍了多个在研药物的最新进展。D-2570 计划用于多个自身免疫性疾病的临床探 索，溃疡性结肠炎 II 期临床试验已开始。格索雷塞片（商品名称安方宁?）已于 2024 年11 月获得国家 药品监督管理局批准上市，适用于治疗至少接受过一种系统性治疗的 KRS G12C 突变型的晚期非小细 胞肺癌（NSCLC）成人患者，多项临床研究正在进行。D-0502 正在国内和国际进行 III 期临床试验， 初步显示良好安全性和抗肿瘤效果。D-0120 完成 IIb 期临床试验，YF087 和 YF550 的临床前研究取得 进展。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 1）益方生物 （千宜投资参与公司特定对象调研） 根据市场公开信息及7月29日披露的机构调研信息，知名私募千宜投资近期对1家上市公司进行了调研， 相关名单如下： ...

调研纪要：益方生物介绍了多个在研药物的最新进展。D-2570计划用于多个自身免疫性疾病的临床探 索，溃疡性结肠炎II期临床试验已开始。格索雷塞片(商品名称安方宁?)已于2024年11月获得国家药品监 督管理局批准上市，适用于治疗至少接受过一种系统性治疗的KRS G12C突变型的晚期非小细胞肺癌 (NSCLC)成人患者，多项临床研究正在进行。D-0502正在国内和国际进行III期临床试验，初步显示良好 安全性和抗肿瘤效果。D-0120完成IIb期临床试验，YF087和YF550的临床前研究取得进展。 证券之星消息，根据市场公开信息及7月29日披露的机构调研信息，鑫元基金近期对1家上市公司进行了 调研，相关名单如下： 1)益方生物(鑫元基金参与公司特定对象调研) 鑫元基金成立于2013年，截至目前，资产管理规模(全部公募基金)2123.27亿元，排名35/210；资产管理 规模(非货币公募基金)1406.43亿元，排名35/210；管理公募基金数162只，排名47/210；旗下公募基金经 理22人，排名63/210。旗下最近一年表现最佳的公募基金产品为鑫元国证2000指数增强A，最新单位净 值为1.23，近一年增 ...

Core Viewpoint - The company is committed to enhancing operational efficiency and management quality through its 2025 "Quality Improvement and Efficiency Enhancement" action plan, focusing on innovation in drug development and protecting the rights of investors, especially small and medium-sized investors [1][12]. Group 1: Business Strategy and Development - The company aims to accelerate the layout of its core pipeline, focusing on major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to developing innovative drugs with independent intellectual property rights [1][2]. - The company has two authorized products on the market, one in the registration clinical trial stage, two in Phase II clinical trials, and multiple preclinical projects, indicating a strong position in research and development [2]. - The company plans to advance the clinical research of its D-2570 product, which has shown promising results in Phase II trials for psoriasis, and will explore its potential in other autoimmune diseases [2][3]. Group 2: Research and Development Capabilities - The company has established a comprehensive R&D system that enhances the success rate of its products and shortens drug development cycles through precise target selection and clinical development processes [2][4]. - The company has a core R&D team with over 20 years of experience in multinational pharmaceutical companies, which strengthens its capabilities in drug design and clinical trial execution [4][5]. - The company has applied for 370 domestic and international invention patents, with 129 granted, ensuring the commercial value of its innovations and reducing potential patent infringement risks [6]. Group 3: Team and Talent Management - The R&D team constitutes over 90% of the company's workforce, with leaders possessing extensive industry experience, which is crucial for the drug development process [7]. - The company plans to implement a new round of equity incentive plans to attract and retain talent, aligning the interests of shareholders and the core team [7]. Group 4: Financial Management and Fund Utilization - The company is focused on improving the efficiency of its fundraising projects and has made adjustments to its headquarters construction project to better meet R&D needs [8]. - In 2025, the company will increase investment in new drug R&D projects, aiming to enhance the efficiency of clinical trials and expand its clinical pipeline [8]. Group 5: Corporate Governance and Compliance - The company is revising its governance structure, including the cancellation of the supervisory board and the enhancement of the board's responsibilities to improve oversight and protect investor rights [9][17]. - The company emphasizes the importance of internal controls and compliance with relevant laws and regulations to ensure effective management of significant matters [9]. Group 6: Information Disclosure and Investor Relations - The company is committed to enhancing the quality of information disclosure and actively engages with investors through various communication channels [10][11]. - The company plans to conduct at least three performance briefings annually to maintain transparency and keep investors informed about its operations and financial status [11].